​

Bright Minds Biosciences Stock (NASDAQ:DRUG)

OwnershipFinancialsChart

Previous Close

$38.03

52W Range

$0.93 - $79.02

50D Avg

$38.77

200D Avg

$10.56

Market Cap

$266.06M

Avg Vol (3M)

$3.06M

Beta

1.13

Div Yield

-

DRUG Company Profile

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

-

IPO Date

Mar 22, 2021

Website

DRUG Performance

DRUG Financial Summary

Sep 23Sep 22Sep 21
Revenue---
Operating Income$-7.40M$-14.74M$-8.76M
Net Income$-7.37M$-15.19M$-8.52M
EBITDA$-7.33M$-14.74M$-8.76M
Basic EPS-$-1.23$-4.74
Diluted EPS-$-1.23$-4.74

Fiscal year ends in Sep 23 | Currency in CAD

Peer Comparison

TickerCompany
ZVSAZyVersa Therapeutics, Inc.
PHIOPhio Pharmaceuticals Corp.
ADTXAditxt, Inc.
REVBRevelation Biosciences, Inc.
RNAZTransCode Therapeutics, Inc.
DRMADermata Therapeutics, Inc.
IMMXImmix Biopharma, Inc.
CYTOAltamira Therapeutics Ltd.
NRBONeuroBo Pharmaceuticals, Inc.
PYXSPyxis Oncology, Inc.
ZURAZura Bio Limited
ELEVElevation Oncology, Inc.
UNCYUnicycive Therapeutics, Inc.